Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of Paraffinoil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04265599
Recruitment Status : Recruiting
First Posted : February 11, 2020
Last Update Posted : February 11, 2020
Information provided by (Responsible Party):
Ebbe Eldrup, MD, DMSc, Herlev Hospital

Brief Summary:
The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease. Subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.

Condition or disease
Hypercalcemia Renal Injury Paraffinoma

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments
Actual Study Start Date : April 30, 2019
Estimated Primary Completion Date : January 31, 2025
Estimated Study Completion Date : January 31, 2025

Primary Outcome Measures :
  1. Concentration of ionized calcium in plasma above normal range = Hypercalcemia [ Time Frame: at first examination or developed during observation period until 2025 ]
    Hypercalcemia in plasma (exploratory not intervention study). yes or no and level.

Biospecimen Retention:   Samples With DNA
Blood samples Muscle tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
General population

Inclusion Criteria:

  • previous intramuscular injection of paraffin or other oil

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04265599

Layout table for location contacts
Contact: Ebbe Eldrup, DMSc +45 38681154
Contact: Simone Theilade, DMSc

Layout table for location information
Herlev Hospital Recruiting
Copenhagen, Denmark
Contact: Ebbe Eldrup, DMSc    +45 38681154   
Contact: Simone Theilade, DMSc   
Sponsors and Collaborators
Herlev Hospital
Layout table for investigator information
Principal Investigator: Ebbe Eldrup, DMSc Herlev Hospital

Layout table for additonal information
Responsible Party: Ebbe Eldrup, MD, DMSc, Principal investigator Consultant Endocrinologist MD DMSc, Herlev Hospital Identifier: NCT04265599    
Other Study ID Numbers: VEK RegionH: H-19010297
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium Metabolism Disorders
Metabolic Diseases
Water-Electrolyte Imbalance